AdC68 + plasmid DNA + tremelimumab + PF-06801591

This is a combination investigational therapy comprising four components: - **AdC68:** A chimpanzee-derived adenoviral vector (chimpanzee adenovirus serotype 68), engineered for use either as a vaccine delivery vehicle or gene therapy platform in cancer therapy. AdC68 vectors are notable for low human seroprevalence and capacity to elicit strong cellular and humoral immune responses[7][9]. - **plasmid DNA:** Used in combination with AdC68 to deliver genes encoding tumor-associated antigens, immune-stimulatory proteins, or other therapeutic sequences, acting as a gene therapy or vaccination strategy against cancer. - **tremelimumab:** A fully human monoclonal antibody targeting Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), functioning as a checkpoint inhibitor that blocks inhibitory signaling in T lymphocytes, resulting in enhanced antitumor immune activity. - **PF-06801591 (sasanlimab):** A monoclonal antibody targeting programmed death-1 (PD-1) receptor, functioning as an immune checkpoint inhibitor by preventing PD-1 interaction with its ligands and thus releasing inhibitory immune signals in the tumor microenvironment[2][4][6][10]. This combination is being investigated for synergistic immune activation: the gene therapy and viral vector prime and boost the immune response against tumor antigens, while the dual checkpoint blockade (tremelimumab and PF-06801591) further amplifies T cell-mediated antitumor effects. The primary, but not exclusive, indication is advanced malignancies, especially solid tumors (notably non-small cell lung cancer and urothelial carcinoma in referenced clinical trials for PF-06801591)[2][8][10].

Other names

AdC68 + plasmid DNA + tremelimumab + PF-06801591